Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lee Carter

Cardiovascular Disease Newport Beach, CA Medical Doctor

NPI 1801904388 CMS profile 126863

351 Hospital Rd Ste 307, Newport Beach, CA 92663

Open in the dashboard

General payments

$11,434

518 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lee Carter of Newport Beach, CA is reported in the CMS Open Payments database as having received $11,434 across 518 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $802 33
2024 General $1,057 39
2023 General $2,271 81
2022 General $1,755 84
2021 General $2,078 107
2020 General $1,471 71
2019 General $1,999 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lee Carter
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Lee Carter were reported at $802. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Lee Carter Cardiovascular Disease median Middle half National median
2019 $1,999 $450 $127–$1,392 $163
2020 $1,471 $242 $77–$751 $114
2021 $2,078 $335 $101–$1,037 $132
2022 $1,755 $395 $121–$1,211 $149
2023 $2,271 $443 $136–$1,283 $160
2024 $1,057 $450 $136–$1,323 $164
2025 $802 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,514 84 payments
  2. Janssen Pharmaceuticals, Inc $1,318 56 payments
  3. Novartis Pharmaceuticals Corporation $1,114 56 payments
  4. Amgen Inc. $1,073 48 payments
  5. Regeneron Healthcare Solutions, Inc. $1,051 39 payments
  6. Pfizer Inc. $792 39 payments
  7. AstraZeneca Pharmaceuticals LP $728 31 payments
  8. Medtronic, Inc. $503 27 payments
  9. E.R. Squibb & Sons, L.L.C. $497 27 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $457 26 payments
  11. Other $2,387 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,412 517 payments
  2. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $1,318 56 payments
  2. JARDIANCE $1,249 71 payments
  3. Repatha $902 42 payments
  4. PRALUENT $850 33 payments
  5. EVKEEZA $730 28 payments
  6. ELIQUIS $713 36 payments
  7. FARXIGA $640 27 payments
  8. ENTRESTO $586 34 payments
  9. PRADAXA $560 36 payments
  10. LifeVest $457 26 payments
  11. Other $4,929 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,320

Median for Cardiology: 2,533

Drug cost

$390,743

Median for Cardiology: $485,213

Branded share of claims

35.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 143 $166,611
Repatha Sureclick Evolocumab Brand 107 $84,241
Xarelto Rivaroxaban Brand 41 $47,942
Praluent Pen Alirocumab Brand 26 $25,266
Farxiga Dapagliflozin Propanediol Brand 25 $21,882
Ozempic Semaglutide Brand 12 $17,594
Entresto Sacubitril/Valsartan Brand 16 $11,902
Pradaxa Dabigatran Etexilate Mesylate Brand 12 $2,242
Rosuvastatin Calcium Generic 126 $1,993
Valsartan Generic 53 $1,753

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$113,866

Medicare's payments for the services billed

Medicare patients

405

Average age 80

Services billed

1,783

186 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Arthritis 53%
Atrial fibrillation 43%
Chronic kidney disease 34%
Diabetes 30%
Heart failure 30%
Cancer 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $199
$199 41 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $155
$155 25 —
Repatha
  • Amgen Inc. $122
$122 107 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $88
$88 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $82
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

518 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record